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Neuroleptic Malignant Syndrome :
Diagnostic Dilemma in the Medically III
Mahmoud A. Parsa, M.D. ,
Andrew J. Picken
and Robert Keating, M.D.

Abstract

Neuroleptic malignant syndrome is a potentiallyfa tal complication if neuroleptic treatment.
It is characterized fry a variery if signs and symptoms associated with autonomic instability, and
hypothalamic and extrapyramidal dysfu nction. Since other medical disorders may mimic its clinical
presentation, the accurate recognition if this syndrome in the medical setting is often a diagnostic
dilemma. Three medically ill patients with a clinical presentation suggestive if neuroleptic
malignant syndromearepresentedhere. The authors discuss the complexity if making the diagnosis,
and qjfer a briefreview if the literature.
Since it was firs t d escribed in 1960, a pproximat ely 1000 cases of neurolep tic
m ali gn a nt syndrom e (NMS) have been report ed in the lit e ra t ure (1-2). Althou gh the
precise pathophysiology is no t well unde rstood , NMS is wid ely recognized as a
pot ent iall y fa tal co m plica t ion of treatmen t wit h neu rol e ptic agents. Studies su ggest
t hat it is relat ed t o decreased ce n t ra l dop a m in e rgic act ivity , most com monly precipita te d by dop am ine D 2 receptor bloc ka de in the stria tal and hypo tha la m ic sys tems
(3) .
Exp e rts have not been a ble to ident ify ac curate ly a subpopu lat ion at inc re ased
risk for developin gth e syndro me . H oweve r, a ge ne t ic co mpone nt ofNMS vulne rability has been hypothesiz ed , a nd a rece nt familial case report proposes th at NMS
susce pt ibility m ay be, in part , a heritabl e cha ract e rist ic (4) . Case reviews su gg est t hat
risk fact ors fo r developing NMS in clud e: I) previou s hist ory ofNMS, 2) intramuscul ar
delivery a nd / or abr up t inc rease in rat e or tot al dosage of neuroleptic agent, 3)
a n tecede n t dop amine a gonist or a n t icholine rg ic m edi ca ti on wit hd rawa l, 4) conc urre n t use of oth er psych otropi c dru gs, 5) e t ha nol a buse or dep e nde nce, 6) pr e-existing
br ain pathology, 7) conc om itan t m edical or n eu rological illn ess, 8) d e hydration, a nd
9) psych omot or ag itat io n (5-7). G ender ra t io of NMS is approximat ely 2: 1 mal e:
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fem al e, with a n ave rage age of onse t of 38-40. Risk facto rs for NMS a re su m ma rized
in T abl e 1.
Diagn osis of NMS re q uires differentiation from clinica lly simi lar synd ro mes
including t he se roto ni n syndrome (8-9), monamine oxidase in hibitor-induced hyperten sive crisis, m al ign ant hype rth ermi a , heat stroke, a nd let ha l ca ta tonia ( 10-11).
Va riou s m edi cal a nd neurological illn esses m ay also resemble NMS , th erefore,
di fferential di agn osis of this synd ro me in a me d ica l se tt ing may be problem atic ( 12).
Inv esti gators have ou tline d di agn osti c crite ria to ass ist in dist ingu ishing NMS fr om
ot he r clinicall y sim ila r en tities (7, 12). Th e major crite ria are bas ed on t he presen ce of
I ) a u to no m ic instabilit y, 2) ex t ra pyram idal dysfun cti on , 3) hypertherm ia , a nd 4)
cloud ed co nsc ious ness . In addition, a variety of a bnormal la bora tory valu es have bee n
out line d as mi nor cri teria; I) elevated serum creat ine kina se (C K) activity over 1000
U / liter, 2) white blood ce ll cou nt (WBC) over 15.0 X 109 E/lit er, 3) eleva te d liver
enzymes, 4) myoglobinuri a, 5) elec trolyte ab no rmalities, and 6) diffuse slowing on
elec t roe nce phalog ra m (13). Diagn osti c cri teria for NMS a re summarized in T abl es 2
a nd 3.
T reat m en t for NMS includ es promp t recogn ition of the syndrom e, imm edi at e
TABLE 1.

Application of Risk Factors for NMS
Case #1

Case # 2

Case # 3

M

ivl
72
MR/CS

M
35
OB S

yes

2.5
no
high
oral
yes

5
yes
high
ora l
no

yes
yes
yes
no
yes

no
yes
yes
no
no

yes
yes
yes
no
no
no
no

Demograph ic

Sex
Age
Psych ia t r ic Diagnosis

67
MR

Neuro leptic R elated

Maxi mu m dose (mg /24 hou rs}'
Initiat ed /Increased dose
Pot en cy
Rout e
Polyph a r macy (psychotropics)

7
yes
high

1M

Medical! N eurological Status

Psych omotor ag itation
Co nc urre n t illn esses
Pr eexi st ing brain patholo gy
Alcoh ol/Subst an ce a buse
De hyd ration
Pr eviou s NMS
Iron deficien cy anemia/

?

?

yes

no

ICase # I received a co mbina tion of t rifluperazine 10 mg an d halope ridol 14 mg over a pe riod
of48 hours.
2Alt hough co ntrove rs ia l, low se rum iron has been re por ted as a pot enti a l ris k factor for NM S
(18) .
Abb reviati on s: 1M; intramuscul a r-MR; mental ret arda tion- CS; chronic schizophre niaOB S; organic brain syndro me.
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dis continuation of psychotropic m edi cations, and institution of supportive th erapy.
Dopaminergic agonists suc h as bromocriptin e, a man tadine , L-dopa , and ca lcium
channel blo ck ers , such as dantrolene sod iu m , have d emon st rat ed effectiveness in
resolution of th e symptoms, and reduction in associa te d m or t ality ( 14). A mort al ity
rat e of 20-30% sec onda ry to co m plica t ions (pulmonary, ren al , cardiovascu lar) ha s
been report ed in untreated cases (15).
W e report three pati ents wh o pr es ent ed to th e m edi cal service wit h fever, a nd
un explain ed e leva te d se r um CK. Following psychi atric co ns u ltation, on e case was
di a gn osed with NMS, a nd the possibility of NMS was ruled out in another. Assessment for NMS in th e third pati ent was difficult du e to a com plex medical pr esent ation.
CASE #1
A 5 7-year-old man was tr an sferred from a nursin g hom e to U nive rsity Hospital s of
Cl evel and for eva lua t ion and treatm ent of a r ight lowe r ex tre m ity fract ure . T he patient 's past
medi cal hist or y was significa nt for gas t roi n tes tina l bleed ing a nd iro n deficie ncy an emia. Hi s
psychi a tri c history was rem ark abl e for ment al re tarda t ion secondary to a febri le illn ess a t age
four. Befor e ad m ission th e patient had been r eceivin g furos emide 20 mg dai ly, iron sulfa te 300
m g twice dail y. Hi s treat me nt a lso included nortript yline 25 mg twic e dai ly a nd trifluperazin e 2
m g twice daily for psych ological an d behavior al a bno rmalities.
On day three of hospit ali zation , following an ort hopedic procedure, t he patient dem onst ra te d incr ea sin g agi ta t ion, a nd hal op eridol in a dosage of2 mg oral or intramuscu lar eve ry 4
hours as need ed , a nd ben zt ropin e were adde d to his ad m ission med ica tions. Ov er th e next two
days, he received a tot al of 14 mg int ramuscul ar halop e rid ol and 2 mg intramuscu lar
triflupera zin e in addition to his st anding regim en . Su bse q ue nt ly, t he pati ent developed motor

TABLE 2.

Application of Keck's Diagnostic Criteria of NMS
Case #1

Case #2

C ase # 3

yes
yes
yes

yes
no
no

yes
yes
yes

yes
yes
yes

no
yes
yes

yes
yes
no

Major Criteria
Hyp erthermia (> = 38°C)
Ex trapyra mi da l Dysfunction '
Aut onomic Dysfunction''

Minor Criterio''
C loude d Co nsc ious ness
Se rum C K > 1000 U / lite r
WB C > 15.0 X 10 9E /lit e r

'T wo or more of t he following: muscu lar rigidity; dystonic reaction ; cogwhe el ing ; pa rkinso nIs m .

2Two or mor e of t he following: fluc tuating blood pr essure; ta chycardia; tach ypn ea ; di aphor esis;
ur inary incontine nce.
3In the abse nce of o ne of th e th r ee major crit eria, pro ba ble d iagnosis is still permitt ed if th e
patie nt clearly me e ts t he two remaining major crit eria , and disp lays one of th e minor crite ria.
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TABLE 3.
Application of Caroff's Diagnostic Criteria o f NMS

Neuroleptic treatm ent within 7 days of on set (2-4
we eks for depot pr ep arations)
Hyperthermia ( > = 38°C)
Muscle rigidity
Five of th e following
Alt ered mental status
Tach ycardi a
Hyper / hypote nsio n
T achypn ea /Hypoxi a
Diaphor esis /Si a lorrhea
Dysarthria /Dysphagia
Tremor
In con t ine nce
CK e leva tion
Myog lobinuria
Leukocyt osis
Absen ce of ot he r e tiolog ies

C ase #1

Case # 2

Case # 3

yes
yes
yes

yes
yes
no

yes
yes
yes

yes
yes
yes
yes
yes
yes
yes
no
yes
no
yes
yes

yes
no
no
no
no
no
yes
no
yes
no
yes
no

yes
yes
yes
no
yes

?
no
no
yes
no
no
no

dysfunction, aspiration pn eumonia , a nd becam e in cr easingly co nfus ed . Antibiot ic the rap y was
initiated to treat th e pn eumonia.
At psychiatric co nsu ltat ion th e patient was diaphoreti c, wit h a n ora l tem pe rature of
38 .9°C, pul se of 104/min, respirat ion of 321 m in, a nd fluctua tin g blood pressur e betw een
160 / 90 to 108/ 50 mmHg. Mental sta tus exa m ina tion reveal ed co nfus ion, di sor ie ntat ion, and
a n inability to co m m un ica te verball y. Neurological exa m ina tion dem on st ra ted marked extra pyr amidal signs, including in cr ea sed muscle ton e, with d iffuse trem or , cogwhee ling, and
lead-pipe rigidity in th e upper ex t re m ities. Serum che m ist ries reveal ed a C K level of 1267
U /lit er, le uk ocytosis (15 .0 X 109 E/ liter), a nd norma l e lec t ro lytes . A tent ative di agn osis of
NMS was made. All psychotropic med ications were di scontinued , suppo rt ive t he ra py was
initiated, and oral bromocryptine 2.5 mg three tim es daily was initiat ed a long with supportive
th erapy.
Ov er th e followin g four days th e patient 's ment al sta t us clea red , ex t ra pyra m ida l symptom s resolved, a nd vit al signs sta bilize d (te m pe ra ture 36.6°C, pul se 72/m in , respirat ion
12/min, and blood pr es sure 120/70 mmH g). Laboratory valu es normal ized , with a C K of 123
U / lit er, and WBC of 7.70 X 109 E/lit er. Bromocriptine wa s dis continued , a nd followin g a full
course of a nt ibio tic th erapy for pn eumonia the pa ti ent was dis ch arged in improved condition.
CASE # 2
A 72 yea r old man with a pr eadm ission di agnosis of ch ro n ic schizo phreni a a nd men ta l
ret ard ation was ho spitalized for eva lua tion a nd treatm ent of wea kn ess , lethargy, a nd fever of
unknown ori gin . His past medi ca l history was significa nt for parkinsoni sm, hyper ten sion,
e m physe ma , with ch ronic bronchit is, a nd a hearing deficit. Past su rgica l hist or y includ ed a
tr ansurethral prost at ect omy, and cho lecys tectomy . Medi cati on s on ad m ission incl ud ed ver a pamil 240 m g d ail y, fluph en a zin e 2.5 mg da ily, ben ztrop ine I mg dail y, a nd ora l a na lges ics.
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Admission findin gs included te mperatu re of 40°C, blood pressure of 118/70 mmH g, pul se
96 / m in, a nd respiration 26/ m in, a mar ked hearing deficit , an d m ild parkinsonism (increase d
mu scle ton e a nd t rem or). Blood tests were not abl e for WB C of 34.5 X 10 9 E/ lit er, incr eased
liver e nzy mes (lac ta te d eh ydrogen ase 27 1 U/liter, a lka line phosphatase 236 U /liter, ga m ma
g lu tamyl t ra nsfe rase 307 U / lite r, aspa rta te am ino- tra nsferase 102 U /lit er, a nd a la nine
a mi notra nsfe rase 125 U / liter), a nd se rum C K of 4543 U/ lit e r (with negative MB ). Electrocard iogra m did not reveal a ny ischemic changes, a nd se pt ic work-u p (cer ebrospinal fluid , blood
a nd uri ne cu lt ures, a nd ches t X- ray) was un reveali ng.
Em piric a nt ibiotic th e rap y for pr esu m ed hepat obil ia ry in fect io n was ini tiated. O ver th e
following day, th e patient deferv esced (te m pe ra t ure 36.6°C), with a marked drop in se ru m C K
( 1467 U / lite r) a nd WB C ( 17.4 X 109 E/ lite r) . H oweve r, a psychiat ric consulta t ion was
obtaine d to eva lua te fo r NMS . On mental stat us exa m ina tion, th e pat ient was a lert , o riente d,
but un abl e to co m m u nica te effec tively because of his hea ri ng deficit. There wa s no evide nce of
ac ute beh avior al or psych ological a bno r ma lity. In th e a bse nce of acute psychotic sympt oms,
dis continuation of fluph en azine wa s recomm ended . Ov er th e su bseq ue n t four days, th e pati ent
cont in ue d to improve, a nd a t th e tim e of di sch arge from th e hospit al , his se rum CK was 398
U / liter WB C was 7.5 X 109 E /lit er, a nd liver e nzymes we re close to norm al.
CASE # 3
A 35-yea r-old man with acq ui re d immunod eficien cy synd rom e (AIDS) d ementia co m plex
an d hyp ert en sion en te re d th e hospit al for eva lua tion a nd t rea t men t of new -on set lethargy,
wea kness, a nd peripheral neu ropathy. Hi s past psychi atri c history was significant for depression a nd one suicide a tte m pt (med ica tio n overdose) . M ed icat ions on admission included
flucon a zol e, acyclovi r, tri methoprim , a nd dap son e. G e ne ral ph ysica l and neurologi cal exa mi na tion d id not reveal a ny sign ifica nt a bnor ma lit ies . On mental status exa m ina t ion, he ex hibite d
ma rk ed a nxie ty a nd ag ita t ion, with mild cognit ive deficit s (impaired memory and conce nt ra tion ), but ot herwise he was free of psyc ho tic or dep ressive symptoms. Admission lab oratori es
were remarka ble only for a se ru m C K of 634 U '/Iiter, WB C of 2.5 X 109 E/liter, a nd lact at e
d eh yd ro gen ase of353 U/lite r.
Early in th e course of hospital izat ion , t he patient 's a nxie ty a nd agitation wors en ed, an d he
becam e ex t re mely co m ba t ive a nd un coop e rat ive with di agn ost ic pro ced u res. Haloperidol, up
to 5 m g d aily, wa s us ed for sedat ion, a nd afte r receiving a tot al of 30 mg over six d ays, his
ph ysical a nd mental co nd ition d et eri orat ed mark edl y. T empe ratu re increased to 38.0°C , with
fluctuat ion s in blood pr essure fro m 110/ 60 mmHg to 120 / 80 mm Hg, a nd pulse rat e up to
140/min. The patient a lso d evelop ed lead -p ipe rigidity in th e ex t re m it ies, hype rreflexia , and
di aphoresis. Organic workup of his sym pto ms was non cont ribut ory, with negative blood , urin e
a nd ce re bro spina l fluid studies. Chest X-ray was norm al, a nd head ma gn eti c resona nce
im aging was remarkable onl y for mild a tro phic cha nges .
At psychiatric cons ulta t ion mental st atus exa m ina t ion reveal ed confusion, stu por, a nd
impai red speech. Rep eat ed che m ist ries were rem arkabl e for a se ru m C K of 50 1 U / lit er a nd
WBC 4. 2 X 109 E /lit er. The possibility of NM S wa s rai sed , a nd hal op eridol was discontinu ed,
with mod est improvem ent in men tal sta tus, a u to no m ic dysfun ct ion , and ex tra pyra m ida l
sym pto ms ove r th e next three days. The pat ient becam e afebri le wit h a tem perature of36 .5°C ,
a le r t, a nd was a ble to follow ve rba l co m mands. Tw o days la te r , t he pa tie nt was st art ed on
a m pho te r icin B for a presum ed funga l infec tion of t he ce nt ra l ne rvou s system, and a fte r five
days ph en othia zin e deri vatives were adde d to his regimen to man age th e gastroint estinal side
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effects of th e antifungal agent. Subsequently th e patient becam e febril e a nd stu porou s, his
motor and autonomic function deteriorated, a nd serum C K incr ea sed to 1161 U / lit er.
Follow-up psychiatric co nsulta t ion, once a gain, suggest ed th e possibil it y of NMS an d
re commended abrupt withdrawal of ph enothiazines . D espit e th e di scontinu at ion of th e
neuroleptic ag ent , no significant improvem ent follow ed , a nd th e patient was tra nsfer red to the
int en sive care unit and subsequently dis charged to a n int ensive nursin g ca re facil ity.
DISCUSSION

First described in the lit erature by Delay a nd Denik er ( 16), as a se rious
complication of treatm ent with neurol eptics, NMS is cha racte rized by hype rth er m ia ,
parkinsonism, and eleva te d serum CK. However, retrospecti ve st udies have dem on strated that this syndrome is easily confused with other clinical probl e m s in com plicate d medical pati ents (17). Our cases illustrat e th e difficulties of di agn osin g NMS in
pati ents with concom ita n t medical illn ess.
Diagnosis of NMS in case # I was bas ed on con sid eration of mult ipl e factors. H is
risks for dev eloping NMS included receiving intramuscul ar high pot en cy neu roleptic
(haloperidol) and increased doses of triftuperazine in th e sett ing of a pre-ex ist ing
brain pathology (m ental ret ardation) a nd other conc ur re nt risk fact ors (see T abl e I).
Evaluation of his clinical presentation satisfied both Keck and Caroff's di agnost ic
criteria of NMS (se e Tables 2 and 3). Although fever cou ld have been att ribut ed to
th e pn eumonia, th e pati ent 's m edical cond ition could not ex plain th e seve re parki nsonism and autonomic instability. Marked resolution of th e sym ptom s following
abrupt withdrawal of neurol eptics, a nd institution of supportive th erap y a nd t rea tm ent with bromocriptin e, furth er supported th e diagnosis of NM S. Fin all y, eleva te d
serum CK may have be en secondary to bone fra cture, but th e dram atic drop in C K
level following dis continuation of haloperidol and trifluperazin e a lso favored th e
diagnosis of NMS. It is of not e that this patient present ed with a history of iron
deficiency anemia, whi ch has been report ed by som e investigators as a pot en tial risk
factor for NMS (18).
In contrast to patient # I, NMS was rul ed out in patient #2 followin g considera tion of his symptoms, clinical course, and lack of th e signifi cant risk factors (see
T abl es 1-3) . The patient had a history of chronic schizophreni a a nd rrient al retard ation, but the absence of any recent cha nge in th e dos e or rout e of ad min istrat ion of
fluphenazin e made th e diagnosis of NMS less likely. The mild ext ra pyra m ida l
symptoms in this patient, although suggestive of NMS , may hav e been d ue to his
pr e-existing parkinsonism. Furthermore, th e course of thi s patient 's illn ess was not
typi cal for NMS. Recent studies hav e shown that th e m ean duration ofNMS following
appropriate treatment is 6.8 days (19). Thus, th e rapid resolution of feve r, leukocytosis, and liver enzym e alterations were more likely due to a n tibiotic th erap y for t he
pr esum ed biliary tract infection, rather the dis continuation of fluph en azi ne.
The present ation and clinical cou rse of patient # 3 illu strat es a d iagnost ic
dil emma. Despite this pati ent 's young ag e, his conc urre n t br ain pathology (AIDSdementia com plex) put him at high risk for NMS wh en ex pose d to high pot e ncy
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neurol eptics (6). Hi s clinical course is cons iste n t wit h NMS by both Keck and Caroff's
di agn ostic cri teria (see T abl es 2 a nd 3) . Furt hermore, th e remission and rel apse of
sym pto ms afte r withd rawal of haloperidol a nd ini ti ation of ph e no t hia zine derivatives
resp ecti vely, also favor the di ag nosis ofNMS . H owever , it is difficult to distinguish th e
neu rol eptic side effects fro m sym pto ms of AIDS-d em e nti a complex . Human immunodeficien cy viru s (H IV ) in fecti on has been associa te d wi t h subacut e e nce pha lit is a nd
ase p tic m eningi ti s cha racte rize d by men tal confus ion progressing to dem enti a, feve r,
m et abolic a bnormalit ies, fat ig ue, a nd movemen t disorde r (20) . Therefore, th e
hyp e rthe rmia, mot or dysfuncti on , and al t ered se nsoriu m in t his pati ent could be
a tt ribu te d to HIV e nce phalopa t hy, es pecia lly in t he view of the overall progression of
th e sym ptoms eve n afte r th e final withdrawal of pheno thiazine derivatives.
These three cases illu strat e the difficulti es tha t clin icians fa ce in acc ura te
id entification of NMS in t he me dica lly ill. Carefu l rev iew of the temporal relationships of drug ad mi nist ra t ion a nd th e se q ue nce a nd nature of clinical manifest ation s
as th e syndro me evolves, fac ilitate th e diagn osis. Even whe n diagnostic un certainty
ex ists, we propose th at in high-risk pati ents, neu rolept ic medications sh ould be
wit hhe ld , a nd non-neuroleptic tr eatm ent strategies be considered to co nt ro l th e
resid ua l behavior probl ems.
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